Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial

European Heart Journal, Journal Year: 2024, Volume and Issue: 45(37), P. 3789 - 3800

Published: July 18, 2024

Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure preserved ejection fraction (HFpEF).

Language: Английский

---

Discovery of Titin and Its Role in Heart Function and Disease

Circulation Research, Journal Year: 2025, Volume and Issue: 136(1), P. 135 - 157

Published: Jan. 2, 2025

This review examines the giant elastic protein titin and its critical roles in heart function, both health disease, as discovered since identification nearly 50 years ago. Encoded by TTN (titin gene), has emerged a major disease locus for cardiac disorders. Functionally, acts third myofilament type, connecting sarcomeric Z-disks M-bands, regulating myocardial passive stiffness stretch sensing. Its I-band segment, which includes N2B element PEVK (proline, glutamate, valine, lysine-rich regions), serves viscoelastic spring, adjusting sarcomere length force response to stretch. The details how alternative splicing of pre-mRNA produces different isoforms that greatly impact tension under physiological pathological conditions. Key posttranslational modifications, especially phosphorylation, play crucial titin’s stiffness, allowing rapid adaptation changing hemodynamic demands. Abnormal modifications dysregulation are linked diseases such failure with preserved ejection fraction, where increased impairs diastolic function. In addition, discusses importance A-band region setting thick filament enhancing Ca² + sensitivity, contributing Frank-Starling Mechanism heart. truncating variants frequently associated dilated cardiomyopathy, outlines potential mechanisms, including haploinsufficiency, disarray, altered regulation. Variants have also been conditions peripartum cardiomyopathy chemotherapy-induced cardiomyopathy. Therapeutic avenues explored, targeting factors RBM20 (RNA binding motif 20) adjust isoform ratios or using engineered tissues study mechanisms. Advances genetic engineering, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), offer promise modifying treat titin-related cardiomyopathies. comprehensive highlights structural, mechanical, signaling function mutations on diseases.

Language: Английский

---

Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7628 - 7628

Published: July 11, 2024

Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD HF are complex still not completely understood include chronic inflammation, oxidative stress, neurohormonal activation. Despite diagnostic prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting date. Moreover, diagnosis this clinical condition challenging. In review article, we aim discuss different pathogenetic spectra these diseases, their relevance, possible targets along remaining knowledge gaps field.

Language: Английский

---

Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review

Cureus, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Heart failure with preserved ejection fraction (HFpEF) is a subtype of congestive heart distinguished by normal fraction. Comorbidities associated its development typically include chronic conditions such as diabetes, hypertension and obesity that restrict the heart's filling pressure. Since reduced (HFrEF) has been subject much research, physicians have always faced problem lack effective therapeutic interventions when treating patients HFpEF. In recent years, there an increase in number research studies to identify medication for Sodium-glucose cotransporter-2 (SGLT-2) inhibitors glucagon-like peptide-1 (GLP-1) receptor agonists, which were initially developed manage shown improvement clinical outcomes HFpEF even absence diabetes. This systematic review aimed gather analyze evidence from randomized controlled trials observational on two drug classes. The Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) 2020 guidelines followed conduct this comprehensive review. To find all relevant studies, we searched three major medical databases, including Web Science, Cochrane Central Register Controlled Trials (CENTRAL), PubMed (NCBI). We identified 13 both classes drugs, some contributed formulating current managing quality included scrutinized using assessment tools, Risk Bias 2 tool Newcastle-Ottawa Scale tool, ensure transparency limit bias lead more reliable findings. Most SGLT-2 demonstrated significant reduction hospitalization rates symptom burden, measured Kansas City Cardiomyopathy Questionnaire (KCCQ) scores functional capacity, 6-minute walk test distance. GLP-1 agonists also improved specifically obese patients, although reductions remain unclear. Improvements capacity observed classes, though metrics not consistently statistically across studies. superiority one over another remains inconclusive due comparing drugs. addition, recently studied, necessitating further class assess long-term outcomes, efficacy non-obese combination inhibitors.

Language: Английский

---

Identification of noval diagnostic biomarker for HFpEF based on proteomics and machine learning

Proteome Science, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 8, 2025

Language: Английский

---

Modulation of GLP-1 signalling as an innovative strategy counteracting the onset of heart failure: potential for natural compound supplementation

Pharmacological Research, Journal Year: 2025, Volume and Issue: 216, P. 107744 - 107744

Published: April 21, 2025

The clinical continuum of heart failure (HF) is commonly divided into four stages (A, B, C and D), but despite the identification its staging, to date, management early phases remains an unmet need. In fact, incomplete knowledge molecular mechanisms associated with comorbidities leading HF onset represents obstacle a targeted therapy. Recently, A B have been further typified and, starting from this novel characterization, aim our review was propose alternative criterion appropriately use GLP-1 RA in association plant-derived polyphenolic extracts. This approach based on selection main underlying asymptomatic that might be prevented or antagonized through administration natural

Language: Английский

---

Eisenmangel bei kardiovaskulären Erkrankungen

Deleted Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 30, 2024

Iron deficiency is worldwide the most frequently occurring of a trace element. Meanwhile, indications are increasing that iron plays relevant role in many cardiovascular diseases and treatment accessible with intravenous administration iron.

Language: Английский

---

Pharmacological management of heart failure: a patient-centered approach

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(16), P. 2151 - 2165

Published: Oct. 22, 2024

Heart failure (HF) is a global health challenge that requires multidisciplinary approach. Despite recent advances in pharmacological and interventional therapy, morbidity mortality these patients remain high. For this reason, because of its interplay with other cardiovascular non-cardiovascular diseases, HF represents major area research, new trials being published every year international guidelines constantly updated.

Language: Английский

---

Predicting cardiac infarctions with reinforcement algorithms through wavelet transform applications in healthcare

Information Sciences, Journal Year: 2024, Volume and Issue: 691, P. 121513 - 121513

Published: Nov. 5, 2024

Language: Английский

---